Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease
暂无分享,去创建一个
R. Dwek | M. Wormald | T. Butters | P. Compain | M. M. Mackeen | O. Martin | C. Boucheron | Valérie Desvergnes | Alan Lavi
[1] J. Sussman,et al. New directions in the treatment of Gaucher disease. , 2004, Trends in pharmacological sciences.
[2] G. Andria,et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement , 2003, Journal of Inherited Metabolic Disease.
[3] R. Dwek,et al. Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation. , 2003, The Biochemical journal.
[4] P. Compain,et al. Design, synthesis and biological evaluation of iminosugar-based glycosyltransferase inhibitors. , 2003, Current topics in medicinal chemistry.
[5] R. Dwek,et al. Therapeutic applications of imino sugars in lysosomal storage disorders. , 2003, Current topics in medicinal chemistry.
[6] P. Compain,et al. A general strategy for the practical synthesis of nojirimycin C-glycosides and analogues. Extension to the first reported example of an iminosugar 1-phosphonate. , 2002, The Journal of organic chemistry.
[7] L. Pickering,et al. Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins. , 2002, The Biochemical journal.
[8] P. Compain,et al. Carbohydrate mimetics-based glycosyltransferase inhibitors. , 2001, Bioorganic & medicinal chemistry.
[9] D. Elstein,et al. Gaucher's disease , 2001, The Lancet.
[10] R. Dwek,et al. Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders. , 2000, Chemical reviews.
[11] R. Dwek,et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis , 2000, The Lancet.
[12] R. Dwek,et al. Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis , 2000 .
[13] David A. Fletcher,et al. The United Kingdom Chemical Database Service , 1996, J. Chem. Inf. Comput. Sci..
[14] M. Horowitz,et al. Mutations causing gaucher disease , 1994, Human mutation.
[15] R. W. Brockman,et al. Reactive 5'-substituted thymidine derivatives as potential inhibitors of nucleotide biosynthesis. , 1986, Journal of Medicinal Chemistry.
[16] I. Pascher,et al. Molecular arrangements in sphingolipids. The crystal structure of cerebroside , 1977 .